Share based payments - Summary of subscription rights outstanding and exercisable (Details)
|
|
|
|
12 Months Ended |
|
|
Nov. 19, 2025
shares
|
Aug. 07, 2025
shares
|
May 27, 2025
shares
|
Dec. 31, 2025
EquityInstruments
€ / shares
|
Dec. 31, 2024
EquityInstruments
€ / shares
|
Dec. 31, 2023
EquityInstruments
€ / shares
|
Dec. 31, 2022
EquityInstruments
€ / shares
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 65.24
|
€ 73.19
|
€ 77.93
|
€ 83.12
|
| Outstanding at the beginning of the year |
|
|
|
11,911,109
|
11,472,520
|
10,816,856
|
|
| Granted during the year |
420,000
|
905,000
|
925,000
|
2,250,000
|
1,381,000
|
1,538,400
|
|
| Exercised during year |
|
|
|
|
|
(61,560)
|
|
| Forfeited during the year |
|
|
|
(232,299)
|
(547,911)
|
(544,676)
|
|
| Expired during the year |
|
|
|
(700,000)
|
(394,500)
|
(276,500)
|
|
| Outstanding at the end of the year |
|
|
|
13,228,810
|
11,911,109
|
11,472,520
|
|
| Exercisable |
|
|
|
8,822,812
|
5,182,941
|
5,836,538
|
2,574,218
|
| Subscription rights |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 65.24
|
€ 73.19
|
€ 77.93
|
|
| Outstanding at the beginning of the year |
|
|
|
11,911,109
|
11,472,520
|
|
|
| Granted during the year |
|
|
|
2,250,000
|
|
|
|
| Forfeited during the year |
|
|
|
(232,299)
|
|
|
|
| Expired during the year |
|
|
|
(700,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
13,228,810
|
11,911,109
|
11,472,520
|
|
| Exercisable |
|
|
|
8,822,812
|
|
|
|
| 2016 (B) allocated on January 2017 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 62.5
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
10,000
|
|
|
|
| Expired during the year |
|
|
|
(10,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
|
10,000
|
|
|
| 2017 allocated on May 2017 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 80.57
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
585,000
|
|
|
|
| Expired during the year |
|
|
|
(585,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
|
585,000
|
|
|
| 2017 RMV allocated on May 2017 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 80.57
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
105,000
|
|
|
|
| Expired during the year |
|
|
|
(105,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
|
105,000
|
|
|
| 2018 allocated on April 2018 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 79.88
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
929,995
|
|
|
|
| Forfeited during the year |
|
|
|
(5,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
924,995
|
929,995
|
|
|
| Exercisable |
|
|
|
924,995
|
|
|
|
| 2018 RMV allocated on April 2018 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 79.88
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
117,500
|
|
|
|
| Outstanding at the end of the year |
|
|
|
117,500
|
117,500
|
|
|
| Exercisable |
|
|
|
117,500
|
|
|
|
| 2019 allocated on April 2019 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 95.11
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
1,144,990
|
|
|
|
| Forfeited during the year |
|
|
|
(17,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
1,127,990
|
1,144,990
|
|
|
| Exercisable |
|
|
|
1,127,990
|
|
|
|
| 2019 RMV allocated on April 2019 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 95.11
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
153,500
|
|
|
|
| Forfeited during the year |
|
|
|
(1,750)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
151,750
|
153,500
|
|
|
| Exercisable |
|
|
|
151,750
|
|
|
|
| 2020 allocated on April 2020 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 168.42
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
1,315,692
|
|
|
|
| Forfeited during the year |
|
|
|
(13,456)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
1,302,236
|
1,315,692
|
|
|
| Exercisable |
|
|
|
1,302,236
|
|
|
|
| 2020 RMV allocated on April 2020 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 168.42
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
179,175
|
|
|
|
| Forfeited during the year |
|
|
|
(11,100)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
168,075
|
179,175
|
|
|
| Exercisable |
|
|
|
168,075
|
|
|
|
| 2021 BE allocated on April 2021 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 64.76
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
1,015,033
|
|
|
|
| Forfeited during the year |
|
|
|
(252)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
1,014,781
|
1,015,033
|
|
|
| Exercisable |
|
|
|
1,014,781
|
|
|
|
| 2021 RMV allocated on April 2021 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 64.76
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
218,925
|
|
|
|
| Forfeited during the year |
|
|
|
(8,325)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
210,600
|
218,925
|
|
|
| Exercisable |
|
|
|
210,600
|
|
|
|
| 2021 ROW allocated on April 2021 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 64.76
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
591,450
|
|
|
|
| Forfeited during the year |
|
|
|
(5,625)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
585,825
|
591,450
|
|
|
| Exercisable |
|
|
|
585,825
|
|
|
|
| 2022 (A) allocated on January 2022 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 46.18
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
30,000
|
|
|
|
| Outstanding at the end of the year |
|
|
|
30,000
|
30,000
|
|
|
| Exercisable |
|
|
|
30,000
|
|
|
|
| 2022 (B) allocated on January 2022 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 50
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
1,000,000
|
|
|
|
| Outstanding at the end of the year |
|
|
|
1,000,000
|
1,000,000
|
|
|
| Exercisable |
|
|
|
1,000,000
|
|
|
|
| 2022 BE allocated on May 2022 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 57.46
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
804,232
|
|
|
|
| Forfeited during the year |
|
|
|
(1,588)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
802,644
|
804,232
|
|
|
| Exercisable |
|
|
|
802,644
|
|
|
|
| 2022 BE allocated on August 2022 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 51.58
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
78,000
|
|
|
|
| Forfeited during the year |
|
|
|
(6,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
72,000
|
78,000
|
|
|
| Exercisable |
|
|
|
72,000
|
|
|
|
| 2022 RMV allocated on May 2022 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 57.46
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
199,069
|
|
|
|
| Forfeited during the year |
|
|
|
(4,780)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
194,289
|
199,069
|
|
|
| Exercisable |
|
|
|
194,289
|
|
|
|
| 2022 ROW allocated on May 2022 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 57.46
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
631,100
|
|
|
|
| Forfeited during the year |
|
|
|
(16,673)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
614,427
|
631,100
|
|
|
| Exercisable |
|
|
|
614,427
|
|
|
|
| 2022 BE/ROW allocated on August 2022 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 51.58
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
60,000
|
|
|
|
| Outstanding at the end of the year |
|
|
|
60,000
|
60,000
|
|
|
| Exercisable |
|
|
|
60,000
|
|
|
|
| 2023 BE allocated on May 2023 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 35.11
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
593,250
|
|
|
|
| Outstanding at the end of the year |
|
|
|
593,250
|
593,250
|
|
|
| 2023 RMV allocated on May 2023 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 35.11
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
100,000
|
|
|
|
| Outstanding at the end of the year |
|
|
|
100,000
|
100,000
|
|
|
| Exercisable |
|
|
|
50,000
|
|
|
|
| 2023 ROW allocated on May 2023 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 35.11
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
496,900
|
|
|
|
| Forfeited during the year |
|
|
|
(28,750)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
468,150
|
496,900
|
|
|
| Exercisable |
|
|
|
235,950
|
|
|
|
| 2023 BE allocated on June 2023 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 38.58
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
200,000
|
|
|
|
| Outstanding at the end of the year |
|
|
|
200,000
|
200,000
|
|
|
| 2023 ROW allocated on November 2023 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 32.99
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
20,000
|
|
|
|
| Outstanding at the end of the year |
|
|
|
20,000
|
20,000
|
|
|
| Exercisable |
|
|
|
10,000
|
|
|
|
| 2024 BE allocated in May 2024 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 26.9
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
667,798
|
|
|
|
| Forfeited during the year |
|
|
|
(50,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
617,798
|
667,798
|
|
|
| 2024 RMV allocated in May 2024 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 26.9
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
21,500
|
|
|
|
| Outstanding at the end of the year |
|
|
|
21,500
|
21,500
|
|
|
| Exercisable |
|
|
|
5,375
|
|
|
|
| 2024 ROW allocated on May 2024 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 26.9
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
602,000
|
|
|
|
| Forfeited during the year |
|
|
|
(62,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
540,000
|
602,000
|
|
|
| Exercisable |
|
|
|
135,000
|
|
|
|
| 2024 BE allocated in October 2024 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 25.88
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
3,500
|
|
|
|
| Outstanding at the end of the year |
|
|
|
3,500
|
3,500
|
|
|
| 2024 ROW allocated in October 2024 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 25.88
|
|
|
|
| Outstanding at the beginning of the year |
|
|
|
37,500
|
|
|
|
| Outstanding at the end of the year |
|
|
|
37,500
|
37,500
|
|
|
| Exercisable |
|
|
|
9,375
|
|
|
|
| 2025 (A) allocated in May 2025 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 25.64
|
|
|
|
| Granted during the year |
|
|
|
925,000
|
|
|
|
| Outstanding at the end of the year |
|
|
|
925,000
|
|
|
|
| 2025 (B) allocated in August 2025 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 28.16
|
|
|
|
| Granted during the year |
|
|
|
905,000
|
|
|
|
| Outstanding at the end of the year |
|
|
|
905,000
|
|
|
|
| 2025 (C) allocated in November 2025 |
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
|
€ 26.75
|
|
|
|
| Granted during the year |
|
|
|
420,000
|
|
|
|
| Outstanding at the end of the year |
|
|
|
420,000
|
|
|
|